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Relaxin family peptide receptor 3
a b s t r a c t
Relaxin family peptide receptor 3 (RXFP3) is a G-protein coupled receptor mainly expressed in the brain
and involved in appetite regulation. Previous studies in lean Wistar rats during the light phase have
shown that the chimeric peptide R3(BΔ23–27)R/I5 suppresses food intake stimulated by an RXFP3
agonist, but has no effect on food intake when administered alone. We wanted to further investigate if
R3(BΔ23–27)R/I5 on its own is able to antagonize the basal tone of the relaxin-3/RXFP3 system and
therefore characterized the pharmacology of R3(BΔ23–27)R/I5 in vivo and in vitro. R3(BΔ23–27)R/I5
was intracerebroventricularly (ICV) injected in diet induced obese (DIO) Wistar rats and food intake was
automatically measured during the dark phase when feeding drive is high. In our hands, R3(BΔ23–27)R/
I5 alone did not have a signiﬁcant effect on food intake during 24 h following administration. Consistent
with previous results, relaxin-3 stimulated food intake in satiated lean rats. R3(BΔ23–27)R/I5 was
characterized in vitro using [35S]-GTPγS binding and cAMP assays, both assessing Gαi-protein mediated
signalling, and dynamic mass redistribution (DMR) assays capturing the integrated cell response. R3
(BΔ23–27)R/I5 showed partial agonist activity in all three functional assays. Thus, since R3(BΔ23–27)R/
I5 displays partial RXFP3 agonist properties in vitro, further in vivo studies including additional tool
compounds are needed to address if antagonizing relaxin-3/RXFP3 basal tone is a therapeutically
relevant mechanism to regulate food intake and body weight.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Relaxin-3 was discovered in 2002 as a member of the insulin sup-
erfamily of polypeptides. Relaxin-3 is a neuropeptide, highly expressed
in the brain together with its receptor RXFP3 (Bathgate et al., 2002;
Burazin et al., 2002; Liu et al., 2003b; Sutton et al., 2004). Insulin/
relaxin polypeptides are formed by two peptide chains (A and B),
cross-linked with disulphide bonds (Schwabe and McDonald, 1977).
The insulin/relaxin peptide family consists of seven members in
human, relaxins 1–3 and insulin-like peptides 3–6. Besides RXFP3,
relaxin-3 is able to activate RXFP1 and RXFP4 receptors in vitro (Liu
et al., 2003a; Sudo et al., 2003) and in vivo (Bathgate et al., 2006;
Otsubo et al., 2010). An RXFP3 speciﬁc agonist tool, designated R3/I5,
has been developed by combining the A chain of INSL5 with the B
chain of relaxin-3 (Liu et al., 2005). By truncating ﬁve amino acids of
the C-terminus from the B chain of R3/I5 and adding an arginine,
another peptide chimera, R3(BΔ23–27)R/I5, was created. This peptide
has been reported as a potent antagonist of the RXFP3 and RXFP4
receptors (Kuei et al., 2007). Recently, it has been suggested that the
pharmacology of R3(BΔ23–27)R/I5 at RXFP3 is more complex, with
R3(BΔ23–27)R/I5 exhibiting weak partial agonist properties with
respect to p38MAPK, ERK1/2 and cAMP signalling (Kocan et al., 2014).
Although the physiological functions of relaxin-3 and RXFP3 are
still being unravelled, they have most prominently been implicated
in regulation of stress responses (Tanaka et al., 2005; Ryan et al.,
2013) and feeding (McGowan et al., 2005). With respect to regulation
of energy balance, acute or chronic ICV administration or injection of
relaxin-3 into hypothalamic sites increases food intake and body
weight in satiated rats (Hida et al., 2006; McGowan et al., 2009).
Moreover, a recombinant virus expressing relaxin-3 injected ICV in
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rats increases food intake involving oxytocin signalling, well known
to increase feeding in rodents (Ganella et al., 2013). Recently, it has
been reported that there is a link between relaxin polymorphisms
and obesity in patients treated with antipsychotic drugs emphasizing
a relationship between relaxin-3 and metabolic syndrome in this
population (Munro et al., 2012).
R3(BΔ23–27)R/I5 is able to inhibit food intake stimulated by the
selective RXFP3 agonist R3/I5 (Kuei et al., 2007). Acute or chronic
central treatment with R3(BΔ23–27)R/I5 does not inhibit food con-
sumption in non-obese rats when given alone (Kuei et al., 2007;
Sutton et al., 2009), but interestingly causes an increase in body
weight (Sutton et al., 2009). In mice, it has recently been reported
that R3(BΔ23–27)R/I5 administered alone reduces food anticipa-
tory activity before meal time, suggesting species differences
between rats and mice in relation to relaxin-3/RXFP3 signalling
networks (Smith et al., 2014).
To assess R3(BΔ23–27)R/I5 as a molecular tool compound for
investigating the relevance of RXFP3 inhibition as anti-obesity tre-
atment, we studied the effect on food intake after ICV injection of R3
(BΔ23–27)R/I5 alone in obese rats during the dark phase when
feeding drive is high. We further investigated antagonistic/agonistic
properties of this peptide towards RXFP3 in vitro.
2. Materials and methods
2.1. Materials
Relaxin-3 was bought from Peprotech (#130-10; New Jersey, NJ,
US) and R3(BΔ23–27)R/I5 was from Phoenix Pharmaceuticals (#035-
66; Burlingame, CA, US). R3(BΔ23–27)R/I5 composition: A – Chain
[pE]DLQTLCCTDGCSMTDLSALC, B – Chain RAAPYGVRLCGREFIRA-
VIFTCR; Disulphide bridges between C7 and C12 of A chain, C8 of A
chain – C10 of B chain and C21 of A chain – C22 of B chain. Molecular
weight 4853.71. HPLC analysis, purity Z95%. Mass spec analysis,
exhibits correct Mw.
Angiotensin was purchased from Sigma (#A9525). Saponin was
from Serva (#34655; Heidelberg, Germany). Artiﬁcial cerebrospinal
ﬂuid (CSF) was purchased from Tocris Biosciences (#3525), Bactrims
(Trimethoprim and Sulfametoxazol) from Roche (Basel, Switzerland)
and Comforions (Ketoprofen) from Orion Pharma Animal Health
(Espoo, Finland). All other chemicals were of reagent grade and
obtained from Sigma-Aldrich (Hamburg, Germany).
2.2. Rats
Male WistarHan rats were obtained from Harlan (Rossdorf,
Germany). Unless otherwise stated, rats were housed individually
in a temperature- and humidity-controlled environment with a
12 h light:12 h dark cycle and were fed with either standard chow
diet (R3 pellet, Lantmännen, Sweden) or with a 45% high fat diet
(D12451, Research Diets Inc, New Brunswick, NJ, US) 9 weeks prior
to experiment start. The study was performed in accordance with
the ethical certiﬁcate approved by the local ethical committee for
animal experimentation.
2.3. Intracerebroventricular cannulation and injection
Lean male WistarHan rats (220–270 g) or DIO WistarHan rats
(450–560 g) were given antibiotic (1.6 mg/rat of Trimethoprim and
8mg/rat of Sulfametoxazol) one day before surgery and one week
after. Rats were anaesthetized with isoﬂurane and secured in a ste-
reotaxic apparatus (Stoelting, Wood Dale, IL, US). The skull was
exposed and a small hole was formed in the skull using a 1.0 mm
drill bead (1.5 mm lateral to the midline and 0.8 mm posterior to
bregma). A guide cannula (Plastics One, Roanoke, Virginia, USA)
4.5 mm length below pedestal was implanted in the lateral ventricle.
Cannulae were secured with two screws and dental compomer
(Revolution Composites, Norwood, MA, USA) cured with an ultraviolet
light (QHL75, Dentsply, York, PA, USA). After suturing, a dummy needle
was inserted to keep the cannula patent, and rats were allowed to
recover from anaesthesia. Rats received post-surgical (3–4 days)
analgesia with Comforions (1–3mg/kg). Rats were left to recover
for 8 days, and all animals used in subsequent experiments had
recovered at least to presurgical weight by the day of experimentation.
Rats were administered ICV via an injection cannula (projecting 1 mm
below the tip of the guide cannula) attached to a length of siliconized
tubing (0.51 mm internal diameter) connected to a 25 μl Hamilton
microsyringe. ICV injections (5 μl) were administered to conscious,
unrestrained rats over a period of 60 s with the rate 5 μl/min. The
cannula placement was checked 8 days after surgery by giving 100 ng
(20 ng/ml) angiotensin ICV and the rats were watched for their ability
to drink water within minutes after injection. Relaxin-3, dissolved in
artiﬁcial CSF, was injected ICV in lean rats (artiﬁcial CSF used as vehicle
control) in the early light phase when the rats were satiated, whereas
R3(BΔ23–27)R/I5, dissolved in sterile physiological saline plus 0.1%
bovine serum albumin, was injected ICV in DIO rats (saline plus 0.1%
bovine serum albumin used as vehicle control) at the beginning of the
dark phase when the drive to eat is high.
2.4. Food intake
Food intake was measured using an in house built automatic
monitoring system allowing continuous measurement of food
intake in undisturbed rats housed in their home cage environment.
In brief, a food container was ﬁlled with either standard chow (R3
pellets) or high fat diet (D12451 pellets). Rats were thereafter put in
individual cages and allowed to be acclimatized to the food intake
system for four days prior to dosing. Food intake was recorded
automatically straight after daily (single) dosing. After 24 h, rats
were placed in their home cage until the next experiment. The data
was analysed using the in house built Pharmlab ofﬂine programme
and cumulative food intake was calculated.
2.5. DNA constructs
cDNAs for human and rat RXFP3 encoding proteins identical to
EMBL accession numbers NM_016568 and AY633763 respectively
were bought from Euroscreen (Brussels, Belgium) and subcloned into
the pIRESneo3 vector (Clontech Laboratories Inc., Palo Alto, CA, USA)
between the AgeI/EcoRI and NheI/AgeI restriction sites respectively.
In the constructs, a consensus Kozak sequence (GCCACC) was inco-
rporated immediately before the start ATG. DNA was ampliﬁed,
isolated and sequenced using standard techniques.
2.6. Cell culturing, transfections and generation of stable cell lines
HEK293s cells were cultured in DMEM medium (#31966-021;
Life Technologies, Carlsbad, CA, US), supplemented with 10% foetal
bovine serum at 37 1C in a humidiﬁed atmosphere with 10% CO2.
Lipofectamine 2000 (Life Technologies) was used for transfections
according to the manufacturer's recommendations. 8 mg plasmid
DNA was used per 75 cm2 ﬂask. DNA constructs were transfected
into HEK293s cells. Resistant polyclonal populations were gener-
ated by selection with Geneticin (0.6 mg/ml, Life technologies) for
two weeks after transfection. Individual clones were isolated using
ﬂow cytometry (FACSVantage SE DIVA, Becton Dickinson, Franklin
Lakes, NJ, US). Stable U-2 OS derived cell lines, U-2 OS-hRXFP3
(#K1569, commercial name: Tango™ RLN3R1-bla U2OS) and U-2
OS-hFFAR4 (custom generated, sequence corresponding to Swis-
sprot accession number Q5NUL3-2) were purchased from Life
Technologies. Medium for U-2 OS derived cell lines was McCoy's
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5AþGlutaMAX-I (#3600, Life technologies) supplemented with 10%
foetal bovine serum,1 mM sodium pyruvate, 25 mMHEPES, 0.1 mM
MEM NEAA, 50 mg/ml Hygromycin B, 200 mg/ml Zeocin, 100 mg/ml
Geneticin.
2.7. [35S]-GTPγS binding assay
Cell membranes were prepared using standard methods and
stored at 80 1C. The protein concentration was determined using
the Pierce BCA Protein Assay Kit (#23225, Thermo Scientiﬁc, Rock-
ford, IL, US).
96-well plate format: Membrane protein (2.5 or 5 mg/well) was
suspended in assay buffer (identical to buffer F in Table 2) (50 mM
HEPES, 200mMNaCl, 1 mMMgCl2, 10 mMGDP, 30 mg/mL Saponin and
0.01% (w/v) BSA, pH 7.4) and incubated with radioligand [35S]-GTPγS
(Perkin Elmer, NEG030, Waltham, MA, US) at 30 1C for 45 min in a
ﬁnal volume of 200 ml. The antagonist potency was determined in
presence of relaxin-3 added at EC80. The reaction was terminated by
rapid ﬁltration of ice-cold wash buffer (50 mM Tris–HCl, 5 mMMgCl2,
50 mM NaCl, pH 7.4) under vacuum in a Micro 96 Harvester (Skatron
Instruments, Lier, Norway) through Filtermat glass-ﬁbre ﬁlters B
(Perkin-Elmer).
384-well plate format: Membrane protein (0.5 mg/well) was sus-
pended in assay buffer identical to buffer S in Table 2 (50 mM HEPES,
40 mM NaCl, 10 mM MgCl2, 3 mM GDP, 30 mg/mL Saponin and 0.01%
(w/v) BSA, pH 7.4) or buffer conditions as indicated in Table 2 and
incubated with radioligand [35S]-GTPγS (Perkin Elmer) at 30 1C for
60 min in a ﬁnal volume of 60 ml. The mixture was transferred to
Millipore Multiscreen HTS 384 FB plates (#MZFBNOW50, Millipore,
Billerica, MA, US) and the reaction was terminated by rapid ﬁltration
of ice-cold wash buffer (50 mM Tris–HCl, 5 mM MgCl2, 50 mM NaCl,
pH 7.4) under vacuum. Bound radioactivity was determined in a
Trilux Microbeta counter (Perkin Elmer).
2.8. cAMP assay
Measurements of cAMP productionwere performed using LANCEs
cAMP kits (PerkinElmer) in a total assay volume of 12 ml/well. In brief,
ligands (relaxin-3 and/or R3(BΔ23–27)R/I5) were dispensed into
small-volume 384-well plates (Greiner) before addition of 4000
cells/well in buffer (Hank's balanced salt solution with Ca2þ and
Mg2þ (HBSS) (Life Technologies), 20 mM HEPES pH7.4 (Life Technol-
ogies), 0.1% BSA (Sigma)). cAMP production was stimulated for 45 min
at 37 1C with 10 mM forskolin (Sigma), 1 mM IBMX (Sigma) and
250 mM Alexa Fluors 647-anti cAMP antibody (LANCE cAMP kit).
The reaction was stopped with detection buffer containing 10 mM
Biotin-cAMP and 15 mM LANCE Eu-W8044 labelled streptavidin (Per-
kinElmer LANCE cAMP kit). cAMP production was detected by homo-
genous time resolved ﬂuorescence (HTRF) (λex¼340 nm, λem¼665
and 615 nm) using a Pherastar (BMG Labtech, Ortenberg, Germany).
cAMP standard curves were included in experiments and used to
convert HTRF data to pM cAMP.
2.9. Dynamic mass redistribution (DMR) assay
DMR assays were performed using an EPIC instrument (Corning,
New York, US).
Two days before assay read, 5000 cells/well were seeded into EPIC
384 well, cell based assay ﬁbronectin coated plates (5042 Corning) and
incubated at 37 1C in a humidity controlled incubator. The cells were
serum starved for 18–24 h before the experiment. On the day of the
experiment, culture medium was removed and replaced with 30 ml
HBSS (with Ca2þ and Mg2þ)/HEPES buffer (20 mM, pH 7.4) with
0.01% BSA. After an initial temperature stabilization for one hour,
followed by a two minutes baseline run in the instrument, 10 ml of
indicated ligands dissolved in buffer were added to the cells. The
resulting change in dynamic mass redistribution was measured in the
instrument during 30 min.
2.10. Radioligand binding assay
Membranes from HEK293s and U-2 OS cells expressing hum RXFP3
were prepared using standard methods. The HEK293s membranes
(5 mg/well) were incubated with radioligand 125I-H3-Relaxin (NEX418,
Perkin Elmer) at increasing concentrations from 0.016 nM up to 2 nM
in buffer (50mM Tris pH 7.4, 1 mM EDTA and 0.5% BSA) at 30 1C. To
determine relative expression level U-2 OS membranes (5 mg/well) and
HEK293s membranes (5 mg/well) were incubated with radioligand at
0.15 nM. Nonspeciﬁc binding was determined in presence of 1 mM R3
(BΔ23–27)R/I5. After 90 min incubation the reaction was ﬁltered
through polyetyleneimine treated ﬁlter plate (Whatman GF/C, 7700-
4301) and washed with icecold buffer under vacuum. Scintillation
liquid was applied to dried ﬁlter plates and bound radioactivity was
determined in a Trilux Microbeta counter (Perkin Elmer).
2.11. Data presentation and statistical analysis
Results from in vivo experiments are presented as mean7S.E.
M. Feeding data were analysed by one-way ANOVA followed by
Dunnett's multiple comparison test. A two-tailed probability of
Po0.05 was considered statistically signiﬁcant. All results from
in vitro experiments are presented as pEC50 or pIC50 values 795%
conﬁdence interval calculated from at least three independent
experiments with the software GraphPad Prism.
3. Results
3.1. Relaxin-3 stimulates food intake in rats
Either relaxin-3 at 90, 180, 360 pmol/rat or vehicle were injected
ICV into male WistarHan rats (n¼8–9 per treatment group) in the
free-feeding state during the early light phase. Rats were placed in
the food intake system in individual cages and data automatically
recorded hourly to the nearest 0.1 g. Cumulative food intake after
1, 2, 4, 6 and 24 h is shown in Fig. 1. All three doses of relaxin-3
signiﬁcantly increased cumulative food intake. Rats administered 90
or 180 pmol relaxin-3 consumed more food throughout the ﬁrst 6 h
than their vehicle-treated counterparts. Rats administered the
highest dose (360 pmol/rat) of relaxin-3 ate more food at all time
points compared to vehicle treated animals.
Fig. 1. Relaxin-3 stimulates food intake. Cumulative 0–24 h food intake in rats ICV
injected with 90, 180, 360 pmol/rat of relaxin-3 or vehicle. * Po0.05, **Po0.01
***Po0.001 versus vehicle. n¼8–9 rats per group. Data shown are mean7S.E.M.
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3.2. Effects of R3(BΔ23–27)R/I5 on food intake in diet-induced obese
rats
DIO rats with high caloric intake were placed in the food intake
system in individual cages and food intake data was automatically
recorded during the experiment. The results of cumulative intake
of high fat diet during 24 h after ICV administration of 2060 pmol/
rat of R3(BΔ23–27)R/I5 (n¼10) or vehicle (n¼12) are presented in
Fig. 2. The results showed no signiﬁcant differences in cumulative
food intake during the dark phase (0–12 h post-injection) between
animals administered R3(BΔ23–27)R/I5 or vehicle at any time
point measured. However, a tendency towards increased cumula-
tive food intake 6 h post-injection of R3(BΔ23–27)R/I5 compared
to vehicle treated animals was observed, but the difference just
failed to reach signiﬁcance (P¼0.0544). The average cumulative
food intake during 24 h in animals administered R3(BΔ23–27)R/I5
or vehicle was 13.571.6 g and 12.870.9 g, respectively.
3.3. Characterization of R3(BΔ23–27)R/I5 pharmacological
properties in vitro
Our in vivo observations led us to investigate if R3(BΔ23–27)R/I5 is
indeed a neutral antagonist on the RXFP3 receptor in vitro. To this end,
we ﬁrst tested R3(BΔ23–27)R/I5 in a [35S]-GTPγS assay. Under initial
buffer conditions containing 200 mM NaCl, R3(BΔ23–27)R/I5 acts as a
potent antagonist with respect to relaxin-3 at EC80 on both human
RXFP3 and rat RXFP3 (Fig. 3). Potency and efﬁcacy data from this
experiment and subsequent in vitro assays are summarized in Table 1.
We further investigated other buffer conditions to see if the
basal activity of RXFP3 could be increased, conditions that could
also potentially improve the possibility to detect weak partial
agonism of compounds. However, since increased basal activity
cause a reduction in assay window, we investigated a wide range
of buffer conditions in the search for maximum stimulated/basal
ratio by varying the concentrations of Naþ , Mg2þ and GDP in the
assay (Table 2; Fig. 4A).
Highest stimulated/basal signal ratio was obtained with 200 mM
NaCl, 10 mM MgCl2 and 10 mM GDP in the buffer, called condition B
(labelled #), similar to the conditions applied in the initial experi-
ment shown in Fig. 3. The resulting data also revealed conditions
where the basal activity of the receptor was increased with reason-
able assay resolution (Fig. 4B). Maximum basal signal, with stimu-
lated/basal signal ratio kept 42 was obtained with 40 mM NaCl,
10 mM MgCl2 and 3 mM GDP in the buffer; condition S (labelled ##).
3.4. R3 (BΔ23–27)R/I5 has partial RXFP3 agonist properties in
functional assays
By decreasing the [NaCl] from 200 mM to 40 mM and the [GDP]
from 10 mM to 3 mM in the assay buffer (condition S), a clear partial
agonism of R3(BΔ23–27)R/I5 was observed in both human RXFP3
and rat RXFP3 in the [35S]-GTPγS assay (Fig. 5). No effect was
observed in membranes from untransfected HEK293s cells.
To test if the agonistic effect observed in the [35S]-GTPγS binding
assay translated to functional effects in intact cells, responses of
relaxin-3 and R3(BΔ23–27)R/I5 in HEK293s cells expressing human
or rat RXFP3 were measured with cAMP assays (Fig. 6). Cells were
treated with forskolin (10 mM) to stimulate cAMP production and
thereby allow detection of Gαi-mediated signalling. Neither relaxin-3
nor R3(BΔ23–27)R/I5 inﬂuenced forskolin-stimulated cAMP produc-
tion in untransfected HEK293s cells (Fig. 6A). Forskolin-stimulated
cAMP production in the absence of RXFP3 ligands was lower in
RXFP3 expressing cells (Fig. 6B and C) compared to untransfected
cells (Fig. 6A), reﬂecting increased ligand independent activation of
the Gαi pathway due to RXFP3 overexpression. Both relaxin-3 and R3
(BΔ23–27)R/I5 inhibited cAMP production in HEK293s-hRXFP3
(Fig. 6B) and HEK293s-rRXFP3 (Fig. 6C) cells, thus exhibiting RXFP3
agonism. In addition to exhibiting partial agonist properties, R3
(BΔ23–27)R/I5 was also able to partly antagonize the response
triggered by relaxin-3 (Fig. 6B and C). Moreover, R3(BΔ23–27)R/I5
concentration response curves run in antagonist-mode and agonist-
mode converge on similar plateau levels. Together, these results
suggest that R3(BΔ23–27)R/I5 is a partial agonist competing with
relaxin-3 for the same binding site. GTPγS and cAMP potency and
efﬁcacy data is shown in Table 1.
We further performed similar cAMP experiments in U-2 OS
cells stably transfected with hRXFP3, or with hFFAR4 as negative
control, to assess pharmacology of the peptides in another cell
system. Neither relaxin-3 nor R3(BΔ23–27)R/I5 inﬂuenced
forskolin-stimulated cAMP production in U-2 OS-hFFAR4 cells
(Fig. 7A). In contrast, both relaxin-3 and R3(BΔ23–27)R/I5 showed
agonist activity in U-2 OS-hRXFP3 cells (Fig. 7B and C). cAMP
potency and efﬁcacy data is shown in Table 1. To relate results
from functional assays to receptor expression levels in HEK293s
and U-2 OS derived cell lines, radioligand binding assays were
performed. The levels of hRXFP3 were estimated to about
20 pmol/mg membrane protein in the HEK293s-hRXFP3 cells
and o1 pmol/mg in the U-2 OS-hRXFP3 cells.
To investigate integrated cell signalling, the response of relaxin-3
and R3(BΔ23–27)R/I5 in HEK293s cells expressing human RXFP3 was
measured in a dynamic mass redistribution (DMR) assay (Fig. 8). The
DMR assay we have used is based on an optical label-free resonant
Fig. 2. Effect of R3(BΔ23–27)R/I5 on food intake. Cumulative 0–24 h food intake in
DIO rats ICV injected with R3(BΔ23–27)R/I5 (2060 pmol/rat) or vehicle. n¼10–12
rats per group. Data shown are mean7S.E.M.
Fig. 3. Characterization of relaxin-3 and R3(BΔ23–27)R/I5 in [35S]-GTPγS binding
assays under initial assay buffer conditions. In a GTPγS assay using membranes
from untransfected HEK293s cells or HEK293s derived cell lines stably expressing
human or rat RXFP3, ascending concentrations of R3(BΔ23–27)R/I5 were used to
generate concentration responses either in the absence or presence of relaxin-3
added at its EC80 concentration. Data shown are mean7S.E.M. of an experiment
run in triplicates and representative for three independent experiments.
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waveguide grating technology which is able to capture the integrated
cell response via all signalling pathways (Fang et al., 2005a, 2005b,
2005c). Upon compound treatment the cellular response was followed
in real time for 30 min. Clear concentration dependent res-
ponses were observed with both relaxin-3 and R3(BΔ23–27)R/I5
(Fig. 8B). No response of either relaxin-3 or R3(BΔ23–27)R/I5 was
observed in untransfected HEK293s cells (Fig. 8A). DMR potency and
efﬁcacy data is shown in Table 1.
4. Discussion
In contrast to the relatively well-known relaxin peptide, little is
known about the functional role of relaxin-3 and its natural receptor
RXFP3. Potential roles in appetite regulation, stress response, as well
as memory and learning have been described (Tanaka et al., 2005;
Nunez et al., 2006; Gundlach et al., 2009). The expression of relaxin-3
is restricted to the central nervous system, while the receptor RXFP3
besides brain is also expressed at low levels in most peripheral
organs analysed, but the function of the receptor in peripheral organs
is not known. Previous work has suggested that relaxin-3 could be
involved in regulation of feeding independent of neuropeptide Y
(NPY), proopiomelanocortin (POMC) or agouti related protein (AgRP)
(McGowan et al., 2005). This has recently been demonstrated using
paraventricular nucleus injection of RAAV1/2-FIB-R3/I5 (recombinant
adeno-associated virus vector driving the secretion of the bioactive
relaxin-3 agonist R3/I5) causing increased feeding probably through
oxytocin signalling independent of NPY, POMC or AgRP (Ganella
et al., 2013). We decided to investigate this potential appetite
regulating target further.
In our hands, relaxin-3 was able to signiﬁcantly increase food int-
ake conﬁrming published data from Hida et al. (2006) and McGowan
et al. (2009) who have shown that food intake after chronic or acute
relaxin 3-injection is increased. In the case of chronic treatment, Hida
et al. (2006) demonstrated that the increase in food intake was
accompanied by an increase of body weight and an increase in the
epididymal fat pad in relaxin-3 treated rats. Later on, the two-chain
peptide R3(BΔ23–27)R/I5 was shown to antagonize the R3/I5 induced
increase food intake in rats. However, no effect of R3(BΔ23–27)R/I5 on
its own was seen (Kuei et al., 2007). Also subchronic (15 days)
treatment with R3(BΔ23–27)R/I5 alone failed to show an effect on
food intake in lean rats (Sutton et al., 2009). R3(BΔ23–27)R/I5 was in
previous studies given at the beginning of the light phase (Kuei et al.,
2007) when the feeding drive is low and into non-obese animals. To
address this, and to search for conditions where we believed the
probability was high to detect an effect of an antagonist alone, we
tested R3(BΔ23–27)R/I5 in DIO rats during the dark phase when the
drive to eat is high.
We here showed that R3(BΔ23–27)R/I5 was not able to reduce
food intake in DIO rats. One possible explanation is that since
appetite is regulated by many different systems, blockade of one of
these (relaxin-3/RXFP3) only have little or no effect on energy
balance. In our study, a tendency (P¼0.0544) towards an increased
food intake was found 6 h post-injection during the dark phase
(Fig. 2), however not statistically signiﬁcant. Interestingly, a sig-
niﬁcant increase in body weight was observed after chronic
administration of R3(BΔ23–27)R/I5 in the study by Sutton et al.
(2009). An alternative explanation is therefore that R3(BΔ23–27)R/
I5 is not a neutral antagonist, but rather has partial agonist
properties, and instead of reducing food intake and body weight
induces the opposite effect (or no effect). However, in contrast to
rats, it was recently reported that central injection of R3(BΔ23–27)
R/I5 alone in mice can inhibit feeding behaviour. Although food
Table 1
In vitro pharmacology of relaxin-3 and R3(BΔ23–27)R/I5. pEC50 and efﬁcacy values 795% conﬁdence intervals were calculated from three independent experiments (except
for relaxin-3 in GTPγS assay which were from two experiments). Efﬁcacy of R3(BΔ23–27)R/I5 was normalized and shown within brackets as % effect, with relaxin-3 deﬁned
as 100%.
Assay Cells Relaxin-3 R3(BΔ23-27)R/I5 R3(BΔ23-27)R/I5
Agonist mode Agonist mode Antagonist mode
hRXFP3 rRXFP3 hRXFP3 rRXFP3 hRXFP3 rRXFP3
GTPγS HEK293s 410.8a,b 410.3a,b 9.3470.27b 9.7970.24b 7.8370.14c 8.8170.11c
(6375%) (5673%)
cAMP HEK293s 10.5970.08 10.4470.11 9.4170.16 10.0570.14 8.1370.15 9.1970.13
(8375%) (7873%)
cAMP U-2 OS 9.4470.10 – 8.4071.13 – – –
(4173%)
DMR HEK293s 9.1370.10 – 8.0870.16 – – –
(2672%)
a In cases where relaxin-3 did not reach a lower plateau, pEC50 is reported as 4the lowest concentration tested.
b Buffer with 40 mM NaCl.
c Buffer with 200 mM NaCl.
Table 2
GTPγS assay buffer optimization. NaCl, MgCl2 and GDP concentrations were varied
according to the table.
Condition [NaCl] (mM) [MgCl2] (mM) [GDP] (lM)
A 200 10 3
B 200 10 10
C 200 3 3
D 200 3 10
E 200 1 3
F 200 1 10
G 100 10 3
H 100 10 10
I 100 3 3
J 100 3 10
K 100 1 3
L 100 1 10
M 80 10 3
N 80 10 10
O 80 3 3
P 80 3 10
Q 80 1 3
R 80 1 10
S 40 10 3
T 40 10 10
U 40 3 3
V 40 3 10
W 40 1 3
X 40 1 10
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intake was not measured after ICV treatment with R3(BΔ23–27)R/
I5, this peptide reduced motivated food seeking suggesting species
differences in response to this peptide (Smith et al., 2014). In the
same study, the single chain peptide R3(B1–22)R was shown to
reduce food consumption. Moreover, central injection of RXFP3
agonists in satiated mice was unexpectedly not orexigenic. One
reason may be that the basal relaxin-3/RXFP3 tone is higher in mice
than in rats, which could be one explanation why an RXFP3 agonist
causes a response in rats but not in mice. A low basal relaxin-3/
RXFP3 tone in rats could also explain, as mentioned in the study by
Sutton et al. (2009), why an RXFP3 antagonist is not able to sup-
press food intake in rats. However, additional experiments with
conﬁrmed neutral antagonists (or inverse agonists) are required to
clarify the species differences regarding relaxin-3/RXFP3 signalling
networks and food intake/body weight.
In light of available in vivo data, we set out to investigate the
pharmacology of R3(BΔ23–27)R/I5 in vitro. In initial [35S]-GTPγS
experiments, R3(BΔ23–27)R/I5 displayed close to neutral antagonism.
We subsequently optimized assay conditions which involved experi-
ments where multiple buffer components were tested at different
concentrations. The experiments revealed not only conditions where
an optimal signal to noise ratio was obtained, but also conditions
where the basal activity of the receptor was increased. As the basal
activity of a receptor is increased, this provides conditions that allow
Fig. 4. Investigation of GTPγS buffer conditions to search for maximum stimulated/basal signal and for elevated basal receptor activity. Buffer conditions in Fig. 4 are
represented by the letters shown in Table 2. Membranes from HEK293s cells expressing human RXFP3 were stimulated with 200 nM relaxin-3 and [35S]-GTPγS binding was
measured. Stimulated/basal activity, and basal activity alone are shown in (A) and (B) respectively. Highest stimulated/basal signal ratio was obtained with condition B (#).
Optimal basal signal with stimulated / basal signal ratio kept 42 was obtained with condition S (##). Data are mean7S.E.M. of an experiment run with eight replicates.
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detection of partial agonism (Harrison and Traynor, 2003). By decreas-
ing sodium ion concentration in the buffer in [35S]-GTPγS assays, the
constitutive activity of a receptor can be inﬂuenced and this may allow
for an improved deﬁnition of the effects of an activator (Szekeres and
Traynor, 1997; Williams et al., 1997). The presence of sodium ions does
improve the agonist stimulated binding of [35S]-GTPγS relative to basal
binding and thus the signal to noise ratio (Harrison and Traynor,
2003). When applying the lower sodium ion concentration in the
assay buffer, we were able to show a clear partial agonism of R3
(BΔ23–27)R/I5 in the [35S]-GTPγS assay.
Since the buffer conditions applied in the [35S]-GTPγS assay diverge
from physiological conditions we further investigated the
pharmacology of R3(BΔ23–27)R/I5 applying cAMP production and
dynamic mass redistribution (DMR) assays on intact cells at physio-
logical salt concentrations. Also with these approaches we were able
to demonstrate partial agonism of R3(BΔ23–27)R/I5. With cAMP
assays, we observed similar potencies for relaxin-3 and R3(BΔ23–
27)R/I5 as with GTPγS, but higher efﬁcacy of R3(BΔ23–27)R/I5 was
observed. We acknowledge that it is not uncommon that determina-
tion of efﬁcacy differ between technologies, depending on for example
how far upstream/downstream in signalling pathways or which
speciﬁc component that is measured. Earlier studies applying CRE
reporter gene assays to measure activation of Gαi signalling have failed
to detect agonism of R3(BΔ23–27)R/I5 (Kuei et al., 2007; Hossain et
Fig. 5. R3(BΔ23–27)R/I5 acts as a partial agonist in a [35S]-GTPγS binding assay using low sodium concentration buffer conditions. Membranes from untransfected HEK293s
cells (A) or HEK293s derived cell lines stably expressing human (B) or rat RXFP3 (C) were applied in the GTPγS assay using buffer condition S. Membranes were treated with
ascending concentrations of relaxin-3 and R3(BΔ23–27)R/I5 as indicated in the ﬁgure (R3, relaxin-3; BΔ, R3(BΔ23–27)R/I5). Data are mean7S.E.M. of an experiment run in
triplicates and representative for two (relaxin-3) and three R3(BΔ23–27)R/I5 independent experiments.
Fig. 6. Characterization of relaxin-3 and R3(BΔ23–27)R/I5 in cAMP assays. HEK293s (A), HEK293s-hRXFP3 (B) and HEK293s-rRXFP3 (C) cells were co-treated with 10 mM
forskolin (to reveal Gαi-dependent signalling) and concentration responses of relaxin-3 and R3(BΔ23–27)R/I5 as indicated. Data is shown as cAMP (pM) produced.
Concentration responses in (B) and (C) were run either in the absence (ag-mode, agonist mode) or presence of 0.8 nM relaxin-3 (R3@EC90, antagonist mode). Relaxin-3 and
R3(BΔ23–27)R/I5 agonism in Fig. 6B and C were normalized and shown as % effect, with relaxin-3 deﬁned as 100% (D) and (E). Data are mean7S.E.M. of an experiment run
with four replicates and representative for three independent experiments. (R3, relaxin-3; BΔ, R3(BΔ23–27)R/I5).
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al., 2009). Besides employing different technologies, one possible
explanation is differences in RXFP3 expression level between cell lines
and studies. The RXFP3 expression in our HEK293s-hRXFP3 cell line
was high (about 20 pmol/mg protein), whereas the level in the U-2
OS-hRXFP3 cells was much lower (below 1 pmol/mg protein). Partial
agonist responses are enhanced when GPCRs are overexpressed since
a large number of receptors are available to achieve active conforma-
tions (reviewed in Kenakin, 2002). In line with this, we observed
higher efﬁcacy of R3(BΔ23–27)R/I5 in HEK293s-hRXFP3 cells com-
pared to the efﬁcacy in the U-2 OS-hRXFP3 cell line as measured with
cAMP assays.
Recently it has been shown that R3(BΔ23–27)R/I5 is a weak
partial agonist for p38MAPK and ERK1/2 signalling (Kocan et al.,
2014). Although not performed in detailed concentration response
experiments, it was also shown in the same study that R3(BΔ23–
27)R/I5 inhibited forskolin stimulated cAMP production, which is
in line with our ﬁndings.
We applied DMR assays to capture the integrated cell response in
real time. Receptor activation results in numerous cellular processes
including elements such as protein recruitment, receptor internaliza-
tion, reorganization of the cytoskeleton and altered cell adhesion,
ultimately leading to mass redistribution within the cell. The DMR
response causes a change in refractive index near the sensor surface,
which can be measured by optical biosensors, as a change in wav-
elength (Fang et al., 2005a, 2005b, 2005c). Partial agonism of R3
(BΔ23–27)R/I5 could be detected with a DMR assay. ATP, which is a
known activator of purinoceptors that are endogenously expressed in
HEK293s cells, was used as a control of cell functionality and viability.
The relaxin-3 and R3(BΔ23–27)R/I5 agonist responses in DMR were
clearly dependent on RXFP3 since no response could be detected in
untransfected HEK293s cells. Both relaxin-3 and R3(BΔ23–27)R/I5
were less potent in DMR than in the other functional assays, but the
difference between the ligands was still approximately one log unit.
Our results from this label-free method, which captures the inte-
grated cell response of intact cells upon ligand treatment, further
strengthens the conclusion that R3(BΔ23–27)R/I5 is a partial agonist.
Studies have been performed to address the structural and func-
tional role of the B-chain in R3(BΔ23–27)R/I5, which is derived from
relaxin-3 (Hossain et al., 2009). Peptides with the extra arginine
residue at the C-terminus not present in relaxin-3 displayed signiﬁ-
cantly increased afﬁnity for RXFP3. Interestingly, the truncated B-chain
R3(BΔ23–27) has been described as a weak agonist (pEC50¼5.957
0.34), whereas no agonist activity was detected with R3(BΔ23–27)R
containing arginine at the C-terminus.
Further characterization of additional antagonists in a range of
suitable paradigms is required to better understand if RXFP3
antagonism is sufﬁcient to reduce food intake and body weight.
Although challenging to develop such tools, a single-chain RXFP3
active peptide, R3 B1–22R, has been described (Haugaard-
Kedstrom et al., 2011), demonstrating the possibility to generate
less complex RXFP3 active compounds. However, it remains to be
shown if this peptide is indeed a neutral antagonist and further
work is required to demonstrate if RXFP3 antagonism represents a
possible anti obesity therapy.
Fig. 7. cAMP assays in U-2 OS derived cell lines. U-2 OS-hFFAR4 (A) and U-2 OS-hRXFP3 (B) cells were co-treated with 10 mM forskolin (to reveal Gαi-dependent signalling)
and concentration responses of relaxin-3 and R3(BΔ23–27)R/I5 as indicated. Data is shown as cAMP (pM) produced. Relaxin-3 and R3(BΔ23–27)R/I5 agonism in Fig. 7B was
normalized and shown as % effect, with relaxin-3 deﬁned as 100% (C). Data are mean7S.E.M. of an experiment run with six replicates and representative for at least three
independent experiments. (R3, relaxin-3; BΔ, R3(BΔ23–27)R/I5).
Fig. 8. R3(BΔ23–27)R/I5 acts as a partial agonist in a dynamic mass redistribution assay. HEK293s (A) and HEK293s-hRXFP3 (B) cells were treated with ATP, relaxin-3 and R3
(BΔ23–27)R/I5 as indicated. The response triggered by ATP was deﬁned to 100%, with relaxin-3 and R3(BΔ23–27)R/I5 stimulated responses normalized to ATP. Data are
mean7S.E.M. of an experiment run in triplicates and representative for three independent experiments.
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